Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Immune T cells can transfer and boost anti-breast cancer immunity.

Thakur A, Rathore R, Kondadasula SV, Uberti JP, Ratanatharathorn V, Lum LG.

Oncoimmunology. 2018 Aug 27;7(12):e1500672. doi: 10.1080/2162402X.2018.1500672. eCollection 2018.

2.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2018 Nov 10. pii: S1083-8791(18)30698-0. doi: 10.1016/j.bbmt.2018.11.004. [Epub ahead of print]

PMID:
30423480
3.

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2018 Oct 31. pii: haematol.2018.200121. doi: 10.3324/haematol.2018.200121. [Epub ahead of print]

4.

Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation.

Bhutani D, Jaiyeoba C, Kim S, Naylor P, Uberti JP, Ratanatharathorn V, Ayash L, Deol A, Alavi A, Revankar S, Chandrasekar P.

Bone Marrow Transplant. 2019 Jan;54(1):164-167. doi: 10.1038/s41409-018-0270-x. Epub 2018 Jul 23. No abstract available.

PMID:
30038352
5.

A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation.

Modi D, Al-Kadhimi Z, Chen W, Jang H, Deol A, Ayash L, Bhutani D, Alavi A, Ratanatharathorn V, Uberti JP.

Am J Hematol. 2018 Aug;93(4):E96-E98. doi: 10.1002/ajh.25035. Epub 2018 Feb 5. No abstract available.

PMID:
29318650
6.

Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.

Modi D, Deol A, Kim S, Ayash L, Alavi A, Ventimiglia M, Bhutani D, Ratanatharathorn V, Uberti JP.

Bone Marrow Transplant. 2017 Nov;52(11):1530-1536. doi: 10.1038/bmt.2017.182. Epub 2017 Sep 4.

PMID:
28869613
7.

Multistate Models on Pleural Effusion after Allogeneic Hematopoietic Stem Cell Transplantation.

Lee J, Modi D, Jang H, Uberti JP, Kim S.

Open Access Med Stat. 2017;7:15-26. doi: 10.2147/OAMS.S125465. Epub 2017 Apr 15.

8.

Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.

Modi D, Jang H, Kim S, Surapaneni M, Sankar K, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Chandrasekar P, Uberti JP.

Support Care Cancer. 2017 Aug;25(8):2593-2601. doi: 10.1007/s00520-017-3670-3. Epub 2017 Apr 2.

PMID:
28365897
9.

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation.

Modi D, Jang H, Kim S, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Uberti JP.

Am J Hematol. 2016 Sep;91(9):E341-7. doi: 10.1002/ajh.24435. Epub 2016 Jul 14.

10.

Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.

Lum LG, Thakur A, Kondadasula SV, Al-Kadhimi Z, Deol A, Tomaszewski EN, Yano H, Schalk DL, Ayash L, Zonder JA, Uberti JP, Abidi MH, Ratanatharathorn V.

Biol Blood Marrow Transplant. 2016 May;22(5):869-78. doi: 10.1016/j.bbmt.2015.12.030. Epub 2016 Jan 28.

11.

Geographic access to hematopoietic cell transplantation services in the United States.

Delamater PL, Uberti JP.

Bone Marrow Transplant. 2016 Feb;51(2):241-8. doi: 10.1038/bmt.2015.246. Epub 2015 Oct 12.

PMID:
26457909
12.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):531-5. doi: 10.1016/j.clml.2015.05.008. Epub 2015 Jun 6.

PMID:
26166312
13.

Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.

Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, Abidi M, Lum LG, Al-Kadhimi Z, Uberti JP.

Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64. doi: 10.1016/j.bbmt.2014.10.004. Epub 2014 Oct 16.

14.

Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.

Ratanatharathorn V, Deol A, Ayash L, Cronin S, Bhutani D, Lum LG, Abidi M, Ventimiglia M, Mellert K, Uberti JP.

Bone Marrow Transplant. 2015 Jan;50(1):106-12. doi: 10.1038/bmt.2014.203. Epub 2014 Oct 6.

15.

Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.

Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, Deol A.

J Clin Apher. 2014 Dec;29(6):293-8. doi: 10.1002/jca.21321. Epub 2014 Apr 3.

PMID:
24700728
16.

Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management.

Macedo FI, Faris J, Lum LG, Gabali A, Uberti JP, Ratanatharathorn V, White MT.

J Burn Care Res. 2014 Nov-Dec;35(6):e431-5. doi: 10.1097/BCR.0000000000000040.

PMID:
24476990
17.

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI.

J Clin Oncol. 2013 Nov 20;31(33):4199-206. doi: 10.1200/JCO.2012.48.3685. Epub 2013 Oct 14.

18.

CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V.

Biol Blood Marrow Transplant. 2013 Jun;19(6):925-33. doi: 10.1016/j.bbmt.2013.03.010. Epub 2013 Mar 22.

19.

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.

Deol A, Abrams J, Masood A, Al-Kadhimi Z, Abidi MH, Ayash L, Lum LG, Ratanatharathorn V, Uberti JP.

Bone Marrow Transplant. 2013 Aug;48(8):1112-6. doi: 10.1038/bmt.2013.10. Epub 2013 Mar 11.

20.

Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Lum LG, Ramesh M, Thakur A, Mitra S, Deol A, Uberti JP, Pellett PE.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1012-22. doi: 10.1016/j.bbmt.2012.01.022. Epub 2012 Feb 5.

21.

Large pericardial effusion as a complication in adults undergoing SCT.

Norkin M, Ratanatharathorn V, Ayash L, Abidi MH, Al-Kadhimi Z, Lum LG, Uberti JP.

Bone Marrow Transplant. 2011 Oct;46(10):1353-6. doi: 10.1038/bmt.2010.297. Epub 2010 Nov 29.

22.

Very late recurrences of leukemia: why does leukemia awake after many years of dormancy?

Norkin M, Uberti JP, Schiffer CA.

Leuk Res. 2011 Feb;35(2):139-44. doi: 10.1016/j.leukres.2010.09.016.

PMID:
20970853
23.

Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.

Uberti JP, Agovi MA, Tarima S, Haagenson M, Gandham S, Anasetti C, Baker KS, Bolwell BJ, Bornhauser M, Chan KW, Copelan E, Davies SM, Finke J, Hale GA, Kollman C, McCarthy PL, Ratanatharathorn V, Ringdén O, Weisdorf DJ, Rizzo JD.

Bone Marrow Transplant. 2011 Jan;46(1):34-43. doi: 10.1038/bmt.2010.81. Epub 2010 Apr 19.

24.

Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD.

Mellon-Reppen S, Ratanatharathorn V, Cronin S, Uberti JP.

Bone Marrow Transplant. 2010 Dec;45(12):1758-9. doi: 10.1038/bmt.2010.58. Epub 2010 Apr 12. No abstract available.

PMID:
20383208
25.

Tacrolimus disposition in the ascitic fluid of a bone marrow transplant patient.

Ibrahim RB, Abidi MH, Al-Kadhimi Z, Uberti JP, Edwards DJ.

Ann Pharmacother. 2010 May;44(5):939-40. doi: 10.1345/aph.1M708. Epub 2010 Apr 6. No abstract available.

PMID:
20371750
26.

Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.

Ratanatharathorn V, Pavletic S, Uberti JP.

Cancer Treat Rev. 2009 Dec;35(8):653-61. doi: 10.1016/j.ctrv.2009.07.004. Epub 2009 Aug 13. Review.

PMID:
19682801
27.

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.

Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ.

Biol Blood Marrow Transplant. 2009 Jul;15(7):777-84. doi: 10.1016/j.bbmt.2009.03.012. Epub 2009 May 13. Review.

28.

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation.

Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S; Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA.

Br J Haematol. 2009 Jun;145(6):816-24. doi: 10.1111/j.1365-2141.2009.07674.x. Epub 2009 Mar 26.

29.

Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.

Ibrahim RB, Abidi MH, Cronin SM, Lum LG, Al-Kadhimi Z, Ratanatharathorn V, Uberti JP.

Biol Blood Marrow Transplant. 2009 Apr;15(4):395-405. doi: 10.1016/j.bbmt.2008.12.487. Epub 2009 Feb 10. Review.

30.

Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.

Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DL.

Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):8-15. doi: 10.1016/j.bbmt.2008.06.006. Review.

31.

Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation.

Ibrahim RB, Abidi MH, Ayash LJ, Cronin SM, Cadotte C, Mulawa J, Jacobson PA, Smith DW, Uberti JP, Edwards DJ.

J Oncol Pharm Pract. 2008 Sep;14(3):113-21. doi: 10.1177/1078155208089846. Epub 2008 Jun 13. Erratum in: J Oncol Pharm Pract. 2008 Dec;14(4):233.

PMID:
18556719
32.

Optimum use of tacrolimus in the prophylaxis of graft versus host disease.

Uberti JP, Cronin S, Ratanatharathorn V.

BioDrugs. 1999 May;11(5):343-58.

PMID:
18031144
33.

Bronchiolitis obliterans following haematopoietic stem cell transplantation.

Soubani AO, Uberti JP.

Eur Respir J. 2007 May;29(5):1007-19. Review.

34.

Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.

Ayash LJ, Ratanatharathorn V, Braun T, Silver SM, Reynolds CM, Uberti JP.

Am J Hematol. 2007 Jan;82(1):6-14.

35.

Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Reddy P, Johnson K, Uberti JP, Reynolds C, Silver S, Ayash L, Braun TM, Ratanatharathorn V.

Bone Marrow Transplant. 2006 Sep;38(5):351-7. Epub 2006 Jul 24.

PMID:
16862167
36.

Do negative or positive emotions differentially impact mortality after adult stem cell transplant?

Hoodin F, Uberti JP, Lynch TJ, Steele P, Ratanatharathorn V.

Bone Marrow Transplant. 2006 Aug;38(4):255-64. Epub 2006 Jun 19. Review.

PMID:
16785869
37.

Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.

Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, Reddy P, Cooke KR, Yanik G, Whitfield J, Jones D, Hutchinson R, Braun T, Ferrara JL, Levine JE.

Biol Blood Marrow Transplant. 2005 Sep;11(9):680-7.

38.
39.

Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.

Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):208-18.

PMID:
15093918
40.

West Nile virus encephalitis causing fatal CNS toxicity after hematopoietic stem cell transplantation.

Reddy P, Davenport R, Ratanatharathorn V, Reynolds C, Silver S, Ayash L, Ferrara JL, Uberti JP.

Bone Marrow Transplant. 2004 Jan;33(1):109-12.

PMID:
14566328
41.

Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.

Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, Ferrara JL, Uberti JP.

Biol Blood Marrow Transplant. 2003 Aug;9(8):505-11.

42.

Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.

Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM, Braun T, Yanik G, Hutchinson R, Ratanatharathorn V.

Biol Blood Marrow Transplant. 2003 Mar;9(3):189-97.

43.

Chronic graft-versus-host disease: clinical manifestation and therapy.

Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP.

Bone Marrow Transplant. 2001 Jul;28(2):121-9. Review.

44.

Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.

Cronin S, Uberti JP, Ayash LJ, Raith C, Ratanatharathorn V.

Bone Marrow Transplant. 2000 Dec;26(11):1247-9.

45.

Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease.

Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, Silver SM, Ferrara JL, Uberti JP.

Ann Intern Med. 2000 Aug 15;133(4):275-9.

PMID:
10929168
46.

Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.

Uberti JP, Silver SM, Adams PT, Jacobson P, Scalzo A, Ratanatharathorn V.

Bone Marrow Transplant. 1997 Jun;19(12):1233-8.

47.

Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation.

Varterasian M, Ratanatharathorn V, Uberti JP, Karanes C, Abella E, Momin F, Kasten-Sportes C, Al-Katib A, Lum L, Heilbrun LK, et al.

Leuk Lymphoma. 1995 Dec;20(1-2):59-65.

PMID:
8750624
48.

Prevention of hemorrhagic cystitis following allogeneic bone marrow transplant preparative regimens with cyclophosphamide and busulfan: role of continuous bladder irrigation.

Turkeri LN, Lum LG, Uberti JP, Abella E, Momin F, Karanes C, Sensenbrenner LL, Haas GP.

J Urol. 1995 Mar;153(3 Pt 1):637-40.

PMID:
7861502
49.

Allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.

Uberti JP, Ratanatharathorn V, Karanes C, Sensenbrenner LL.

Leuk Lymphoma. 1994 Aug;14(5-6):379-85. Review.

PMID:
7812196
50.

Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.

Schultz KR, Ratanatharathorn V, Abella E, Eisenbrey AB, Karanes C, Lum LG, de Planque MM, Uberti JP, Ravindranath Y, Sensenbrenner LL.

Bone Marrow Transplant. 1994 Jun;13(6):817-22.

PMID:
7920320

Supplemental Content

Loading ...
Support Center